DoD awards $717.8M for Anthrax Vaccine Absorbed (AVA) to Emergent BioDefense, raising value-for-money questions

Contract Overview

Contract Amount: $7,178,000 ($7.2M)

Contractor: Emergent Biodefense Operations Lansing LLC

Awarding Agency: Department of Defense

Start Date: 2026-01-04

End Date: 2029-09-30

Contract Duration: 1,365 days

Daily Burn Rate: $5.3K/day

Competition Type: NOT AVAILABLE FOR COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: FOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA))

Place of Performance

Location: LANSING, INGHAM County, MICHIGAN, 48906

State: Michigan Government Spending

Plain-Language Summary

Department of Defense obligated $7.2 million to EMERGENT BIODEFENSE OPERATIONS LANSING LLC for work described as: FOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA)) Key points: 1. The contract's significant value warrants scrutiny regarding cost-effectiveness and alternative sourcing. 2. Limited competition for this critical biodefense supply raises concerns about price discovery. 3. The long duration of the contract (over 3 years) necessitates ongoing performance monitoring. 4. Dependence on a single supplier for a vital vaccine presents supply chain risks. 5. This procurement highlights the challenges in maintaining domestic biodefense capabilities. 6. The fixed-price contract structure shifts some risk to the government if costs escalate.

Value Assessment

Rating: questionable

The awarded amount of $717.8 million for Biothrax (Anthrax Vaccine Absorbed) over a period extending to September 2029 appears substantial. Benchmarking this against historical procurement data for similar biodefense countermeasures is crucial. Given the sole-source nature of this award, it is difficult to assess if the pricing reflects competitive market rates or if there is an opportunity for cost savings through broader competition or alternative vaccine development. The government is reliant on Emergent BioDefense for this critical supply, which may limit its leverage in price negotiations.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This approach is typically used when only one responsible source can provide the required supplies or services. For a critical biodefense asset like the anthrax vaccine, this may be justified due to specialized manufacturing capabilities or existing government stockpiling agreements. However, the lack of competition prevents market forces from driving down prices and ensuring the best possible value for taxpayer dollars.

Taxpayer Impact: Sole-source awards limit the government's ability to secure the most cost-effective pricing, potentially leading to higher expenditures for taxpayers compared to a competitive procurement.

Public Impact

The primary beneficiaries are the U.S. military personnel who require protection against anthrax exposure. The contract ensures the continued supply of the Anthrax Vaccine Absorbed (AVA), a critical component of the nation's biodefense preparedness. The geographic impact is primarily centered around the manufacturing facilities of Emergent BioDefense in Michigan, with broader national implications for public health security. The contract supports jobs within the biopharmaceutical manufacturing sector, particularly at Emergent BioDefense's facilities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition and potentially increases costs.
Long-term contract duration may not adapt to evolving threats or alternative solutions.
Dependence on a single supplier creates significant supply chain vulnerability.
Past performance issues with Emergent BioDefense's manufacturing raise quality and reliability concerns.

Positive Signals

Ensures continued availability of a critical biodefense vaccine.
Supports domestic manufacturing capabilities for essential medical countermeasures.
Fixed-price contract provides some cost certainty for the government.

Sector Analysis

The biopharmaceutical sector, particularly the segment focused on vaccines and biodefense, is characterized by high R&D costs, stringent regulatory requirements, and significant government investment. This contract falls within the niche of biodefense manufacturing, where a limited number of companies possess the specialized expertise and facilities to produce critical countermeasures. The market size for such specialized vaccines is driven by national security needs and government stockpiling programs, making it distinct from the broader commercial vaccine market.

Small Business Impact

This contract does not appear to include specific small business set-aside provisions. Given the specialized nature of biopharmaceutical manufacturing and the sole-source award to a large entity, the direct impact on small businesses is likely minimal. However, Emergent BioDefense may engage small businesses as subcontractors for specific services or supplies, though this is not explicitly detailed in the provided data.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Defense's contracting and program management offices. The Defense Contract Management Agency (DCMA) would likely be involved in monitoring performance and ensuring compliance. Transparency regarding the specific terms, performance metrics, and any deviations from the contract would be subject to standard government oversight procedures. Inspector General involvement would be triggered by specific allegations of fraud, waste, or abuse.

Related Government Programs

Biodefense Countermeasures
Vaccine Procurement
Strategic National Stockpile
Department of Health and Human Services (HHS) BARDA Contracts

Risk Flags

Sole-source award
Potential for price inflation due to lack of competition
Supplier's history of manufacturing quality issues
Long-term contract duration may not reflect evolving needs
Criticality of the product creates high dependence on a single vendor

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $7.2 million to EMERGENT BIODEFENSE OPERATIONS LANSING LLC. FOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA))

Who is the contractor on this award?

The obligated recipient is EMERGENT BIODEFENSE OPERATIONS LANSING LLC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $7.2 million.

What is the period of performance?

Start: 2026-01-04. End: 2029-09-30.

What is Emergent BioDefense's track record with government contracts, particularly for vaccine production?

Emergent BioDefense has a significant history of contracting with the U.S. government for biodefense products, including the anthrax vaccine. However, the company has faced scrutiny and criticism regarding manufacturing quality control issues, particularly at its Bayview facility, which led to a halt in production and significant financial repercussions. These past issues raise concerns about the reliability and consistency of their production capabilities, necessitating rigorous oversight and quality assurance measures for any current or future contracts. The company has also been involved in other large-scale government procurements, some of which have been subject to review for performance and value.

How does the pricing of this anthrax vaccine contract compare to historical government procurements or market rates?

Directly comparing the pricing of this $717.8 million contract to historical procurements is challenging without access to detailed historical contract data and specific unit costs. However, given the sole-source nature of this award, it is reasonable to infer that the pricing may not reflect the full benefit of competitive bidding. Historically, sole-source contracts can sometimes result in higher prices than if the government had solicited bids from multiple qualified vendors. Benchmarking against the price per dose or per treatment course from previous contracts, adjusted for inflation and any changes in manufacturing processes or raw material costs, would be necessary for a thorough value assessment. The government's reliance on Emergent BioDefense for this critical vaccine likely limits its negotiating power.

What are the primary risks associated with relying on a single supplier for the anthrax vaccine?

The primary risks associated with relying on a single supplier, such as Emergent BioDefense for the anthrax vaccine, are multifaceted. Firstly, there is a significant supply chain vulnerability; any disruption at the supplier's manufacturing facility, due to technical issues, natural disasters, labor disputes, or quality control failures, could lead to shortages of this critical medical countermeasure. Secondly, the lack of competition can lead to higher prices and potentially less incentive for the supplier to innovate or improve efficiency. Thirdly, if the supplier faces financial difficulties or decides to exit the market, the government would face immense challenges in finding and qualifying an alternative supplier, especially for a product with a long and complex manufacturing process. This dependence underscores the strategic importance of maintaining robust domestic biodefense manufacturing capabilities.

What is the expected effectiveness and duration of immunity provided by the Anthrax Vaccine Absorbed (AVA)?

The Anthrax Vaccine Absorbed (AVA), marketed as BioThrax, is indicated for the prevention of disease caused by *Bacillus anthracis*. It is administered as a series of injections. Clinical studies have shown that AVA is effective in preventing inhalational anthrax when administered prior to exposure. The recommended vaccination schedule involves an initial series of injections followed by annual booster doses to maintain immunity. The duration of immunity can vary among individuals, but the annual booster is intended to sustain protective levels. The vaccine's effectiveness is a critical component of U.S. biodefense strategy, aiming to protect military personnel and potentially civilian populations in the event of an anthrax attack.

How does this contract align with the U.S. government's broader biodefense and public health preparedness strategies?

This contract aligns with the U.S. government's overarching strategy to maintain a robust biodefense capability and ensure preparedness against biological threats, including anthrax. The Anthrax Vaccine Absorbed (AVA) is a cornerstone of this strategy, particularly for protecting military personnel who may be deployed to regions where anthrax exposure is a risk. By securing a supply of AVA through this contract, the Department of Defense aims to ensure that its forces have access to this vital protection. This procurement also supports the domestic manufacturing base for essential medical countermeasures, contributing to national security and public health resilience. However, the sole-source nature and past performance issues associated with the supplier necessitate careful management and potential exploration of alternative or supplementary solutions.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT AVAILABLE FOR COMPETITION

Solicitation Procedures: ONLY ONE SOURCE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Emergent Biosolutions Inc.

Address: 3500 N MARTIN LUTHER KING JR BLVD, LANSING, MI, 48906

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $66,882,000

Exercised Options: $21,534,000

Current Obligation: $7,178,000

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: W911SR24D0001

IDV Type: IDC

Timeline